FDA accepts Aquestive’s Anaphylm resubmission for review
AQST•The FDA accepted Aquestive Therapeutics’ resubmitted application for Anaphylm, a sublingual film for severe allergic reactions, including anaphylaxis. The Class 2 review has a target decision date of March 16, 2027.
1. Application review
The FDA accepted Aquestive Therapeutics’ resubmitted application for Anaphylm, a sublingual film for severe allergic reactions, including anaphylaxis. The Class 2 review has a target decision date of March 16, 2027.
